KR900013961A - 기억력 및 학습력 증강 또는 인식 또는 정신장해 치료용 d-시클로세린 및 d-알라닌 함유 조성물 - Google Patents

기억력 및 학습력 증강 또는 인식 또는 정신장해 치료용 d-시클로세린 및 d-알라닌 함유 조성물 Download PDF

Info

Publication number
KR900013961A
KR900013961A KR1019900003482A KR900003482A KR900013961A KR 900013961 A KR900013961 A KR 900013961A KR 1019900003482 A KR1019900003482 A KR 1019900003482A KR 900003482 A KR900003482 A KR 900003482A KR 900013961 A KR900013961 A KR 900013961A
Authority
KR
South Korea
Prior art keywords
therapeutically effective
effective amount
alanine
cycloserine
ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019900003482A
Other languages
English (en)
Korean (ko)
Inventor
에이.코르디 알렉시스
알.잔스 미카엘
Original Assignee
파울 디. 마투카이티스
지.디.썰 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파울 디. 마투카이티스, 지.디.썰 앤드 캄파니 filed Critical 파울 디. 마투카이티스
Publication of KR900013961A publication Critical patent/KR900013961A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Detergent Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1019900003482A 1989-03-15 1990-03-15 기억력 및 학습력 증강 또는 인식 또는 정신장해 치료용 d-시클로세린 및 d-알라닌 함유 조성물 Ceased KR900013961A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32427989A 1989-03-15 1989-03-15
US324,279 1989-03-25
US473,241 1990-02-06
US07/473,241 US5061721A (en) 1989-03-15 1990-02-06 Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder

Publications (1)

Publication Number Publication Date
KR900013961A true KR900013961A (ko) 1990-10-22

Family

ID=26984373

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900003482A Ceased KR900013961A (ko) 1989-03-15 1990-03-15 기억력 및 학습력 증강 또는 인식 또는 정신장해 치료용 d-시클로세린 및 d-알라닌 함유 조성물

Country Status (17)

Country Link
US (1) US5061721A (cg-RX-API-DMAC7.html)
EP (1) EP0387867B1 (cg-RX-API-DMAC7.html)
JP (1) JP2963720B2 (cg-RX-API-DMAC7.html)
KR (1) KR900013961A (cg-RX-API-DMAC7.html)
AT (1) ATE88890T1 (cg-RX-API-DMAC7.html)
AU (1) AU624917B2 (cg-RX-API-DMAC7.html)
CA (1) CA2010635C (cg-RX-API-DMAC7.html)
DE (1) DE69001503T2 (cg-RX-API-DMAC7.html)
DK (1) DK0387867T3 (cg-RX-API-DMAC7.html)
ES (1) ES2055197T3 (cg-RX-API-DMAC7.html)
FI (1) FI901289A7 (cg-RX-API-DMAC7.html)
GR (1) GR3008225T3 (cg-RX-API-DMAC7.html)
IE (1) IE64130B1 (cg-RX-API-DMAC7.html)
IL (1) IL93562A (cg-RX-API-DMAC7.html)
NO (1) NO901198L (cg-RX-API-DMAC7.html)
NZ (1) NZ232809A (cg-RX-API-DMAC7.html)
PT (1) PT93424B (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153193A (en) * 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5302609A (en) * 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
WO1994022437A2 (en) * 1993-03-29 1994-10-13 Queen's University At Kingston Method for treating amyloidosis
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
WO1996015788A1 (en) * 1994-11-23 1996-05-30 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
JPH11501619A (ja) * 1995-02-15 1999-02-09 ベアーズデン バイオ，インコーポレイテッド アルキルカルボキシアミノ酸−カイネートレセプターのモジュレーター
EP0956292A4 (en) 1996-07-22 2003-07-30 Univ Utah Res Found CONANTOKINES
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
AU735389B2 (en) 1996-07-22 2001-07-05 Cognetix, Inc. Use of conantokins
EP1073432B1 (en) * 1998-04-14 2007-08-15 The General Hospital Corporation Use of d-serine or d-alanine for treating schizophrenia
US6551993B1 (en) * 1999-08-16 2003-04-22 Thomas Jefferson University Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20050096396A1 (en) * 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
CA2442330A1 (en) * 2001-03-29 2002-10-10 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US6717012B2 (en) * 2001-04-02 2004-04-06 Neuromolecular, Inc. Antioxidant nitroxides and nitrones as therapeutic agents
ES2314056T3 (es) * 2001-05-02 2009-03-16 Blanchette Rockefeller Neurosciences Institute Activadores de la anhidrasa carbonica para mejorar el aprendizaje y la memoria.
EP1487542A1 (en) * 2002-03-15 2004-12-22 H. Lundbeck A/S Use of asc-1 inhibitors to treat neurological and psychiatric disorders
EP2260844A1 (en) * 2003-05-27 2010-12-15 Merz Pharma GmbH & Co. KGaA Combination of an NMDA Receptor Antagonist and a Selective Serotonin Reuptake Inhibitor for the Treatment of Depression and other Mood Disorders
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
EP1660634A4 (en) * 2003-08-08 2009-02-18 Burnham Inst P16-mediated regulation of NMDA receptors
KR20070007276A (ko) 2003-12-29 2007-01-15 제이슨 맥데빗 재발성 의학적 증상을 치료하기 위한 조성물 및 방법
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
BRPI0519243A2 (pt) 2004-12-22 2009-01-06 Neurochem Int Ltd mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide
ATE481096T1 (de) 2005-04-06 2010-10-15 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
TW200716088A (en) 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
DK2089417T3 (en) 2006-10-12 2015-03-23 Bhi Ltd Partnership Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid
WO2008124814A2 (en) * 2007-04-10 2008-10-16 Mcdevitt Jason P Sublingual formulations of d-cycloserine and methods of using same
BRPI0918868B8 (pt) 2008-09-18 2021-05-25 Naurex Inc compostos moduladores do receptor de nmda e composições compreendendo os mesmos
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
TWI544923B (zh) * 2009-12-29 2016-08-11 何應瑞 用於治療神經退化性疾病之醫藥組合物
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
WO2011100585A1 (en) 2010-02-11 2011-08-18 Joseph Moskal Secondary structure stabilized nmda receptor modulators and uses thereof
JP5689026B2 (ja) * 2010-06-17 2015-03-25 株式会社 資生堂 水中油型乳化皮膚化粧料
CA2826180C (en) * 2011-01-31 2020-09-01 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
EP2931291B1 (en) 2012-12-11 2021-10-20 The McLean Hospital Corporation Xenon treatment as an adjunct to psychotherapy for psychiatric disorders
PE20151416A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
EP2951186B1 (en) 2013-01-29 2018-07-25 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US9758525B2 (en) 2013-01-29 2017-09-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
JP2016506962A (ja) 2013-01-29 2016-03-07 ノーレックス, インコーポレイテッドNaurex, Inc. スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
KR102410989B1 (ko) 2013-01-29 2022-06-17 앱티닉스 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
US9877951B2 (en) 2015-02-12 2018-01-30 College Of William And Mary Method for treating dementia
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
KR102465758B1 (ko) 2016-08-01 2022-11-09 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
AU2017306158B2 (en) 2016-08-01 2021-10-14 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
IL286107B2 (en) 2016-08-01 2024-09-01 Aptinyx Inc Spiro-lactam nmda receptor modulators and usesthereof
JP7036792B2 (ja) 2016-08-01 2022-03-15 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
WO2020252384A1 (en) * 2019-06-14 2020-12-17 Vorsanger Gary Treatment methods utilizing oxytocin receptor agonists
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
CN114786668B (zh) * 2019-11-27 2024-07-16 诺罗瑞韦有限公司 用于治疗抑郁症的环丝氨酸和锂的组合疗法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3428730A (en) * 1967-06-30 1969-02-18 Hamao Umezawa Antibacterial mixture of o-carbamyl-d-serine and d-4-amino-3-isoxazolidone
US4031231A (en) * 1974-06-13 1977-06-21 Merck & Co., Inc. Antibacterial composition comprising 3-fluoro-D-alanine or deutero analog in combination with auto-antagonist inhibitor
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers

Also Published As

Publication number Publication date
FI901289A7 (fi) 1990-09-16
EP0387867A1 (en) 1990-09-19
PT93424B (pt) 1996-08-30
CA2010635A1 (en) 1990-09-15
GR3008225T3 (cg-RX-API-DMAC7.html) 1993-09-30
IE64130B1 (en) 1995-07-12
NO901198L (no) 1990-09-17
AU5073490A (en) 1990-09-20
NO901198D0 (no) 1990-03-14
IL93562A (en) 1996-01-31
DE69001503T2 (de) 1993-09-09
DK0387867T3 (da) 1993-06-01
PT93424A (pt) 1990-11-07
IL93562A0 (en) 1990-11-29
ES2055197T3 (es) 1994-08-16
CA2010635C (en) 2001-03-06
AU624917B2 (en) 1992-06-25
EP0387867B1 (en) 1993-05-05
FI901289A0 (fi) 1990-03-15
US5061721A (en) 1991-10-29
ATE88890T1 (de) 1993-05-15
JPH03148221A (ja) 1991-06-25
NZ232809A (en) 1992-05-26
IE900921L (en) 1990-09-15
DE69001503D1 (de) 1993-06-09
JP2963720B2 (ja) 1999-10-18

Similar Documents

Publication Publication Date Title
KR900013961A (ko) 기억력 및 학습력 증강 또는 인식 또는 정신장해 치료용 d-시클로세린 및 d-알라닌 함유 조성물
ATE419858T1 (de) Krillextrakte zur prävention und/oder behandlung von herz-kreislauf-erkrankungen
ATE219674T1 (de) Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika
CA2339221A1 (en) Extracts of feverfew (tanacetum parthenium) against inflammatory disorders
DE69533940D1 (de) Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
DE69433870D1 (de) Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren
KR940018089A (ko) 내부조직의 방사선 손상에 대한 예방 및 처치방법
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
RU94002133A (ru) 6-хлор-5-фтор-3-(2-теноил)-2-оксиндол-1-карбоксамид как аналгезирующее и противовоспалительное средство
ES2136167T3 (es) Composiciones de idebenona para tratar la enfermedad de alzheimer.
RU94037555A (ru) Железосодержащая композиция для предотвращения анемии, способ ее изготовления и способ лечения анемии
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
IL101675A (en) Method and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors
RU93048600A (ru) Натуральный поливитаминный комплекс "леветон"
RU95102611A (ru) Способ лечения туберкулеза легких
KR880004810A (ko) 소화성 궤양 치료제
EA200401295A1 (ru) Статиновая терапия для усиления поддержания когнитивной функции
PE20040932A1 (es) Metodo de mejora de la circulacion sanguinea
KR890015746A (ko) 메게스트롤 아세테이트로 aids 악액질을 치료하는 방법
KR900017599A (ko) 종양 치료용 약학 조성물
HUP9701606A2 (hu) Szulbutiamin alkalmazása bizonyos pszichomotoros és pszichointellektuális rendellenességek kezelésére használható gyógyszerkészítmények előállítására
RU93018067A (ru) Способ лечения кавернозной формы туберкулеза
RU95122262A (ru) Способ лечения повреждений периферических нервов при травмах конечностей

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19900315

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19950315

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19900315

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19980213

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19980506

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19980213

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I